Founded back in 2012, Exscientia plc went public on Nasdaq in October 2021, raising over $300m – a huge amount for a biotech that is yet to bring a drug into the clinic on its own. However, it was ahead of the game being the first company to automate drug design and the first to have an AI-designed molecule enter clinical trials (albeit a partnered asset).
The company’s most advanced, wholly owned drugs are in IND-enabling studies. EXS74539 is a selective, reversible and brain penetrant LSD1 inhibitor being studied in both hematology and solid tumors